Literature DB >> 29244213

Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Open-Access ALS Clinical Trials cohort.

Nimish J Thakore1, Brittany R Lapin2, Erik P Pioro1,3.   

Abstract

INTRODUCTION: Rate of decline of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) score is a common outcome measure and a powerful predictor of mortality in ALS.
METHODS: Observed rate of decline (postslope) of ALSFRS-R, its linearity, and its relationship to decline at first visit (preslope) were examined in the Pooled Resource Open-Access ALS Clinical Trials cohort by using longitudinal mixed effects models.
RESULTS: Mean ALSFRS-R postslope in 3,367 patients was -0.99 points/month. Preslope and postslope were correlated and had powerful effects on survival. ALSFRS-R trajectories were slightly accelerated overall, but slope and direction/degree of curvature varied. Subscore decline was sequential by site of onset. Respiratory subscore decline was the least steep. DISCUSSION: Variable curvilinearity of ALSFRS-R trajectories confounds interpretation in clinical studies that assume linear decline. Subscore trajectories recapitulate phenotypic diversity and topographical progression of ALS. ALSFRS-R is better used as a multidimensional measure. Muscle Nerve 57: 937-945, 2018.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  ALSFRS-R; amyotrophic lateral sclerosis; longitudinal mixed effects models; phenotypic variability; prognosis; slope; trajectory

Mesh:

Year:  2018        PMID: 29244213     DOI: 10.1002/mus.26042

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  9 in total

1.  Modelling disease course in amyotrophic lateral Sclerosis: pseudo-longitudinal insights from cross-sectional health-related quality of life data.

Authors:  Tino Prell; Nayana Gaur; Robert Steinbach; Otto W Witte; Julian Grosskreutz
Journal:  Health Qual Life Outcomes       Date:  2020-05-01       Impact factor: 3.186

2.  IL6 receptor358Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis.

Authors:  Marlena Wosiski-Kuhn; Mac Robinson; Jane Strupe; Phonepasong Arounleut; Matthew Martin; James Caress; Michael Cartwright; Robert Bowser; Merit Cudkowicz; Carl Langefeld; Gregory A Hawkins; Carol Milligan
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-10-14

3.  The rise and fall of fasciculations in amyotrophic lateral sclerosis.

Authors:  James A Bashford; Aidan Wickham; Raquel Iniesta; Emmanuel M Drakakis; Martyn G Boutelle; Kerry R Mills; Chris E Shaw
Journal:  Brain Commun       Date:  2020-02-20

4.  Prediction of survival in amyotrophic lateral sclerosis: a nationwide, Danish cohort study.

Authors:  Anne-Lene Kjældgaard; Katrine Pilely; Karsten Skovgaard Olsen; Anders Hedegaard Jessen; Anne Øberg Lauritsen; Stephen Wørlich Pedersen; Kirsten Svenstrup; Merete Karlsborg; Helle Thagesen; Morten Blaabjerg; Ásta Theódórsdóttir; Elisabeth Gundtoft Elmo; Anette Torvin Møller; Lone Bonefeld; Mia Berg; Peter Garred; Kirsten Møller
Journal:  BMC Neurol       Date:  2021-04-17       Impact factor: 2.474

5.  Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials.

Authors:  Simon Witzel; Felix Frauhammer; Markus Otto; Albert C Ludolph; Petra Steinacker; David Devos; Pierre-François Pradat; Vincent Meininger; Steffen Halbgebauer; Patrick Oeckl; Joachim Schuster; Simon Anders; Johannes Dorst
Journal:  Transl Neurodegener       Date:  2021-08-26       Impact factor: 8.014

6.  Exploring the association between outcome measures to guide clinical management in patients with amyotrophic lateral sclerosis.

Authors:  Michelle J Sanfilippo; Mary E Layshock; Leslie Keniston
Journal:  J Phys Ther Sci       Date:  2022-08-03

7.  Motor unit number index (MUNIX) in the D50 disease progression model reflects disease accumulation independently of disease aggressiveness in ALS.

Authors:  Theresa Ebersbach; Annekathrin Roediger; Robert Steinbach; Martin Appelfeller; Anke Tuemmler; Beatrice Stubendorff; Simon Schuster; Meret Herdick; Hubertus Axer; Otto W Witte; Julian Grosskreutz
Journal:  Sci Rep       Date:  2022-09-26       Impact factor: 4.996

8.  Long-term edaravone efficacy in amyotrophic lateral sclerosis: Post-hoc analyses of Study 19 (MCI186-19).

Authors:  Jeremy Shefner; Terry Heiman-Patterson; Erik P Pioro; Martina Wiedau-Pazos; Shawn Liu; Jeffrey Zhang; Wendy Agnese; Stephen Apple
Journal:  Muscle Nerve       Date:  2019-11-11       Impact factor: 3.217

Review 9.  Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS.

Authors:  Namita A Goyal; James D Berry; Anthony Windebank; Nathan P Staff; Nicholas J Maragakis; Leonard H van den Berg; Angela Genge; Robert Miller; Robert H Baloh; Ralph Kern; Yael Gothelf; Chaim Lebovits; Merit Cudkowicz
Journal:  Muscle Nerve       Date:  2020-01-22       Impact factor: 3.217

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.